Mandate

Vinge advises Adelis Equity Partners on the establishment of Adelis Equity Partners Fund IV

March 03, 2025 Private Funds

Vinge has advised Adelis Equity Partners on the establishment of Adelis’ fourth flagship fund: Adelis Equity Partners Fund IV.

The fund, which was significantly oversubscribed, held its final closing on 28 February 2025 after having raised commitments of EUR 1.6 billion from an investor base consisting of leading pension funds, foundations and fund-of-funds across Europe and North America, and from the Adelis team. The fund raise entails a more than 50% increase in commitments relative to the predecessor fund, Adelis Equity Partners Fund III. Since its commencement in 2013, Adelis invests in well-positioned companies in the Nordic and DACH regions and has to date made 45 platform investments and more than 260 add-on acquisitions.

Vinge’s team primarily consisted of Mattias Schömer, Nils Unckel, Martin Cronsioe, Ulf Nilsson, Mikaela Reinhammar, Anton Sjökvist, Emelie Svanberg, Tobias Onegård Karlsson, Viktoria Wnuk, Rebecka Margolin, Saga Meyer Viklund and Emelie Zingmark.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025